Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases, Request for Applications (RFA) Number CI06-006, 17104 [E6-4932]
Download as PDF
<![CDATA[
17104
Federal Register / Vol. 71, No. 65 / Wednesday, April 5, 2006 / Notices
(4) Discovering potential testing
problems so that laboratories/testing
sites can adjust procedures to eliminate
them;
(5) Comparing individual laboratory/
testing site results to others at a national
and international level, and
from the last OMB submission. In
addition, participants are required to
submit results twice/year after testing
mailed performance evaluation samples.
There is no cost to the respondents
other than their time.
(6) Consulting with CDC staff to
discuss testing issues.
Participants in the MPEP HIV Rapid
Testing program are required to
complete a laboratory practices
questionnaire survey annually. This
questionnaire has a number of changes
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form
Frequency of
responses
Average
burden per
response
Total burden
hours
HIV Rapid Testing Questionnaire ....................................................................
HIV Rapid Testing Results Booklet .................................................................
750
750
1
2
20/60
10/60
250
250
Total ..........................................................................................................
........................
........................
........................
500
Dated: March 29, 2006.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E6–4919 Filed 4–4–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panels (SEP): Development
and Testing of New Medications for the
Treatment of Emerging Infectious
Diseases, Request for Applications
(RFA) Number CI06–006
wwhite on PROD1PC61 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel (SEP): Development and Testing of
New Medications for the Treatment of
Emerging Infectious Diseases, RFA Number
CI06–006.
Time and Date: 12 p.m.–4 p.m., April 25,
2006 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to: Development and Testing of
New Medications for the Treatment of
Emerging Infectious Diseases, RFA Number
CI06–006.
For Further Information Contact: Christine
Morrison, PhD, Scientific Review
Administrator, Office of Public Health
Research, Centers for Disease Control and
VerDate Aug<31>2005
18:34 Apr 04, 2006
Jkt 208001
Prevention, 1600 Clifton Road, NE., Mailstop
D–72, Atlanta, GA 30333, Telephone 404–
639–3098.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: March 30, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–4932 Filed 4–4–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10066]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
AGENCY:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
The notices is being published based
on the settlement agreement in
Weichardt v. Thompson (Weichardt).
Publication of this notice in the Federal
Register will occur simultaneously with
publication of the proposed regulation
CMS–4105–P, that is also based on the
Weichardt v. Thompson (Weichardt)
agreement.
1. Type of Information Collection
Request: New Collection.
Title of Information Collection:
Medicare and Medicare Advantage
Programs; Notification Procedures for
Hospital Discharges—Generic Notice of
Hospital Non-Coverage—Detailed
Explanation of Hospital Non-Coverage.
Use: Under 42 CFR 405.1205,
405.1206, 422.620, and 422.622,
hospitals and Medicare Advantage plans
must deliver to beneficiaries and
enrollees who are receiving inpatient
hospital services, advance notice of
discharge on the day before discharge. If
the beneficiary chooses to dispute the
discharge, the beneficiary is entitled to
an expedited determination by a Quality
Improvement Organization (QIO) about
whether the provider’s coverage
decision is correct. Upon request for an
expedited review of the discharge
decision, hospitals and Medicare
Advantage plans must deliver detailed
notices to the QIO and beneficiaries/
enrollees.
Form Number: CMS–10066 (OMB#:
0938–New).
Frequency: Other: Distribution.
Affected Public: Individuals or
Households, Business or other for-profit,
Not-for-profit institutions and Federal,
State, Local or Tribal Government.
Number of Respondents: 6057.
Total Annual Responses: 12,750,000.
Total Annual Hours: 1,461,498.
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 71, Number 65 (Wednesday, April 5, 2006)]
[Notices]
[Page 17104]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-4932]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panels (SEP): Development and Testing of New Medications for
the Treatment of Emerging Infectious Diseases, Request for Applications
(RFA) Number CI06-006
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting:
Name: Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel (SEP): Development and Testing of New
Medications for the Treatment of Emerging Infectious Diseases, RFA
Number CI06-006.
Time and Date: 12 p.m.-4 p.m., April 25, 2006 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters to be Discussed: The meeting will include the review,
discussion, and evaluation of applications received in response to:
Development and Testing of New Medications for the Treatment of
Emerging Infectious Diseases, RFA Number CI06-006.
For Further Information Contact: Christine Morrison, PhD,
Scientific Review Administrator, Office of Public Health Research,
Centers for Disease Control and Prevention, 1600 Clifton Road, NE.,
Mailstop D-72, Atlanta, GA 30333, Telephone 404-639-3098.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: March 30, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E6-4932 Filed 4-4-06; 8:45 am]
BILLING CODE 4163-18-P
